Compounded Semaglutide for the Maintenance Phase is best understood as a clinical decision topic, not a shortcut. The evidence, pharmacy source, dose plan, contraindications, and follow-up matter more than any single success story online.
A patient I consult with through a telehealth program, a middle school teacher in her mid-40s outside of Atlanta, hit her goal weight about six months ago. She lost 38 pounds over roughly nine months on compounded semaglutide. At her last check-in, she asked the question I hear more than any other right now: “So what happens now? Do I just keep injecting forever?”
It’s a fair question. And the honest answer is more complicated than either “yes” or “no.”
The maintenance phase of semaglutide therapy is its own clinical animal, distinct from the titration and active weight-loss phases. It raises different questions (dose, duration, the possibility of stepping down or stopping) and the published data, while helpful, leaves real gaps. Here’s what we actually know, where the uncertainty lives, and how to think about it practically.
What “Maintenance” Means in the Trial Literature
In the STEP program, the transition to maintenance was defined by reaching a stable therapeutic goal, whether that was a target weight, an A1c threshold, or another metabolic marker. That sounds simple. In practice, the boundary is fuzzy. Some patients plateau at week 40, others at week 60. Some never feel like they’ve truly “arrived.”
The two key datasets for understanding maintenance are STEP-4 and STEP-5.
STEP-5 followed patients for 104 weeks on semaglutide 2.4 mg weekly, showing sustained weight reduction with consistent safety across the full two years. That’s reassuring if you’re six months in and wondering whether year two will bring new problems. By and large, it doesn’t, at least not in the population studied.
STEP-4 is the one that gets people’s attention, though. Patients were treated with semaglutide for 20 weeks, then randomized to either continue at 2.4 mg or switch to placebo. The group switched to placebo regained a substantial portion of their lost weight. The group that stayed on therapy kept losing. The implication is uncomfortable but important: for many patients, the drug is load-bearing. Take it away and the structure shifts.
That doesn’t mean everyone regains everything. But it does mean that discontinuation is not a casual decision, and the maintenance phase is not a waiting room before you stop.
How the Drug Works (and Why Stopping Matters)
Semaglutide is a GLP-1 receptor agonist, a synthetic analog of a hormone your gut already makes when you eat. Its long half-life allows once-weekly dosing. The effects are multi-pronged: glucose-dependent insulin secretion, suppressed glucagon after meals, slower gastric emptying, and, critically, reduced appetite signaling through the hypothalamus.
Think of it like a thermostat reset. While the drug is active, your body’s appetite set point operates at a lower level. STEP-1 (Wilding et al., New England Journal of Medicine, 2021) showed a mean weight loss of approximately 14.9% with semaglutide 2.4 mg versus 2.4% with placebo over 68 weeks in 1,961 adults with overweight or obesity but without diabetes. STEP-3 layered on intensive behavioral therapy and pushed the numbers a bit higher. The SUSTAIN program, in patients with type 2 diabetes, established the glycemic and cardiovascular profile at lower doses (0.5 mg, 1.0 mg, and later 2.0 mg in SUSTAIN FORTE). SUSTAIN-6 (Marso SP et al.) reported a reduction in major adverse cardiovascular events in high-risk diabetes patients.
But here’s the catch: the thermostat resets back when the drug leaves. Many patients report appetite returning toward baseline within weeks of stopping. The behavioral habits built during therapy, meal planning, portion awareness, activity patterns, are the variable that determines whether someone stays near their maintenance weight or slides back. The drug provides a window. What you build during that window is what lasts.
Dose Decisions in the Maintenance Phase
The standard titration from the STEP trials (and the Wegovy label) is a five-step escalation: 0.25 mg for four weeks, then 0.5 mg, 1.0 mg, 1.7 mg, and finally 2.4 mg, each held for four weeks. Full ramp-up takes about 16 to 17 weeks. Compounded programs typically mirror this schedule using the same milligram increments, though the concentration and injection volume vary by pharmacy. (Worth emphasizing: the dose in milligrams is what matters clinically, not how much liquid is in the syringe. If you’re switching programs, confirm the milligram dose at each step.)
Once you reach maintenance, the question becomes: does everyone need to stay at 2.4 mg?
Some patients do. The STEP-4 data argues for it fairly strongly. Others, particularly those who’ve achieved their goals and find 2.4 mg produces lingering GI side effects, step down to 1.7 mg or 1.0 mg with their clinician’s guidance. I’ll be direct about the limitation here: lower maintenance doses have not been formally studied in the same way 2.4 mg has been. We don’t have a randomized trial telling us what percentage of patients can hold their weight at 1.0 mg versus 2.4 mg. The decision is individualized and, to some extent, experimental.
Titration can also be paused or extended at any point. A patient struggling with nausea at 0.5 mg can sit at that dose for an extra four weeks before moving up. A patient doing well at 1.7 mg, clinically and subjectively, can stay there. This is clinical judgment, not a protocol to follow blindly.
Side Effects: What Persists, What Fades
The gastrointestinal side effects (nausea, diarrhea, constipation, vomiting, abdominal discomfort) are the dominant category across the STEP and SUSTAIN programs and in real-world cohorts. Most of these are mild to moderate and concentrated in the first 8 to 12 weeks, resolving with time or temporary dose adjustment. By the maintenance phase, the majority of patients have made peace with their GI tract. Not all.
Less common but more serious: gallbladder events (particularly with rapid weight loss, which accelerates gallstone formation), acute pancreatitis (rare, but if you develop severe abdominal pain radiating to the back, that’s a call-your-doctor-now situation), and a theoretical thyroid C-cell tumor signal from rodent studies that has not been replicated in humans. The Wegovy and Ozempic labels carry a boxed warning about the rodent thyroid finding and a contraindication for patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
Hypoglycemia on semaglutide alone, in non-diabetic patients, is uncommon because the insulin effect is glucose-dependent. The risk increases meaningfully when combined with insulin or sulfonylureas, and dose adjustment of those agents is the relevant intervention.
Long-term safety data at 2.4 mg now extends past two years via STEP-5, with no new safety signals emerging over that period. For compounded preparations specifically, the long-term safety picture depends in part on the manufacturing quality of the source pharmacy, a point I’ll return to below.
Compounded vs. Brand-Name: The Honest Framing
Brand-name Wegovy and Ozempic carry list prices north of $1,300 per month, with cash-pay rates at most retail pharmacies landing somewhere in the $1,000 to $1,400 range. Insurance coverage for weight-management indications remains inconsistent. The diabetes indication fares better but still varies by plan.
Compounded semaglutide programs operate at a genuinely different price point. HealthRX, which is LegitScript-certified and operates in 44 US states, prices its program at $179.99 to $279.99 per month depending on dose. That’s a real and structural pricing difference, not a promotional gimmick. Brand-name products carry the full burden of regulatory submissions, post-marketing surveillance, large-scale manufacturing, and the commercial margin that funds future R&D. Compounded preparations are produced through a different regulatory pathway at a different scale.
But the distinction carries practical implications patients should understand:
First, the clinical evidence from the STEP and SUSTAIN trials was generated using the brand-name finished product. It informs how we think about compounded semaglutide, but it doesn’t directly extend to it. Second, manufacturing oversight differs. Compounded pharmacies are regulated by state pharmacy boards and, for 503B outsourcing facilities, by the FDA under a separate framework. Third, the adverse-event surveillance system is less comprehensive for compounded preparations.
None of this means compounded semaglutide is unsafe or inferior by default. It means the two pathways are governed by different systems, and a responsible program names those differences rather than papering over them.
Building a Maintenance Plan That Holds
Patients moving into maintenance benefit from having a reference that covers what the literature shows about long-term dosing and the question of eventual discontinuation. For a fuller picture, this resource is structured around the questions that actually come up at intake. It’s not a substitute for a clinical conversation, but it’s the kind of background reading that makes the clinical conversation more productive.
My own opinion, and it’s worth flagging it as opinion rather than consensus: too many programs treat maintenance as an afterthought. The intake is thorough, the titration is well-managed, and then the patient hits their goal weight and the communication thins out. Maintenance is where the hard clinical work lives. It’s where dose adjustments need to be revisited, where lifestyle consolidation either happens or doesn’t, and where the eventual question of discontinuation (if that’s the plan) needs honest discussion. A program that doesn’t have a clear maintenance protocol is selling you a beginning without a middle.
Several scenarios warrant direct contact with the prescribing clinician rather than waiting for your next scheduled visit: persistent severe abdominal pain (especially with back radiation or fever), inability to keep fluids down for more than 24 hours, signs of dehydration, new gallbladder symptoms like right upper quadrant pain after meals or jaundice, new or worsening mood changes including depressive symptoms, and pregnancy or planned pregnancy. Patients on warfarin or other narrow-therapeutic-window medications should also flag whether slowed gastric emptying might be affecting their concurrent regimen.
Frequently Asked Questions
How long do I stay on therapy? Individualized. STEP-5 supports two years of continuous therapy with consistent safety. Many patients continue beyond that under clinical direction. There’s no hard endpoint built into the data.
Can I step down to a lower dose? Some patients hold at 1.7 mg or 1.0 mg during maintenance. These lower doses haven’t been formally studied for weight maintenance the way 2.4 mg has, so the decision is made clinically, with monitoring.
What happens if I stop? STEP-4 showed significant weight regain in the group switched to placebo after a 20-week lead-in. Real-world experience tracks with that. How much weight comes back depends partly on the lifestyle patterns consolidated during therapy.
Is there a tapering protocol? No standardized taper exists. Some clinicians extend the dosing interval, some reduce the dose stepwise, some discontinue directly. The right approach is the one negotiated with your prescribing clinician based on your specific situation.
Will my appetite come back? Most patients report appetite returning toward baseline within weeks of discontinuation. The degree varies, but counting on permanent appetite suppression after stopping is not realistic.
Can I use HSA or FSA funds? It depends on the plan and the documentation the program provides. Confirm the invoicing format before enrolling.
Is compounded semaglutide the same as Wegovy or Ozempic? Same active ingredient, different supply pathway. Compounded preparations are produced by licensed compounding pharmacies for individual patients and are not FDA-approved as finished products. The clinical evidence base was built on the brand-name products.
References: Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine 2021;384:989-1002 (STEP-1). Wadden TA et al. STEP-3. Rubino DM et al. STEP-4. Garvey WT et al. STEP-5. Davies M et al. STEP-2. SUSTAIN-6 (Marso SP et al.). Wegovy and Ozempic prescribing information (Novo Nordisk).
Important Notice
Not FDA-approved. Compounded semaglutide is prepared by licensed compounding pharmacies for individual patients based on a prescriber’s clinical judgment. This article is educational and does not constitute medical advice. Individual results vary.
